16/96

Fee Transmittal & Extension

FEE AUTHORIZATION /AMENDMENT TRANSMITTAL Attorney's Docket No: SYI (SYNE225/C4-US)								
Serial No. 08/182,183		Filing Da May 23,		Examine Mariann	r e P. Allen		Group Art Unit 1812	
In Re Application of Lin et al. for GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR								
TO THE ASSISTANT COMMISSIONER OF PATENTS:								
Applicant(s) petition(s) for the following extension of time under 37 C.F.R. 1.136(a):								
One month of original due date (\$110.00)								
Two months of original due date (\$370.00)								
Three months of original due date (\$870.00)								
Four months of original due date (\$1,360.00)								
X A response in connection with the matter for which this extension is requested:								
X is filed herewith.								
has been filed.								
The response is the filing of a continuation application having an express abandonment conditioned								
	the granting of a filin							
الستنسا	companying papers i							
The accompanying papers include amended claims the fee for which has been calculated as follows:								
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(2)		AIMS AS AMENDE		T (6)		(7)	
(1)	(2) Claims remaining after amendment	(3)	(4) Highest number previously paid for	(5) No. of ext claims present	Rate		(7) Additional Fee	
Total Claims	39	Minus	74 =	0	x \$22	=	0	
Indep. Claims	5	Minus	15 =	0	x \$76	=	0	
	· ·		dditional Fee for this		ent			
	in 2 is less than the en				l' in thic chace		•	
If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space. *If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.								
The following other fees are incurred by the accompanying papers.								
Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$ A duplicate copy of this petition is attached.								
If an additional extension of time is required, please consider this a petition therefore.								
The Commissioner is hereby authorized to charge any additional fees which may be required by the								
accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.								
Please Send Future Correspondence To: U.S. Patent Operations/DRC								
M/S 10-1-B Daniel R. Curry								
AMGEN INC. Attorney for Applicants Amgen Center Registration No.: 32,727								
1840 Dehavilland Drive Phone: (805) 447-8102								
Thousand Oaks, California 91320-1789 Date: January 5, 1996								

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United Sta	stee Postal Service as first class mail in an envelope addressed to Assistant
Commissioner of Patents, Washington, D.C. 20231, on the date appearing bell	
January 5, 1996	Nota & arrette
Date	Note J. Wyger





AMGEN

RECYCLABLE

Amgen Center 1840 Dehavilland Drive Thousand Oaks California 91320-1789

Inventors Names: Lin et al.

Invention Title: GLIAL CELL LINE-DERIVED

NEUROTROPHIC FACTOR

Filing Date: May 23, 1994

Serial No.: **08/182,183**

Date Listing Prepared: January 3, 1996

Docket No.: SYNE-225-E

MACINTOSH OPERATING SYSTEM 7.1/Microsoft Word 5.1a

CAUTION

Patentin Release 1.0 ver. l.25

FLOPPY DISK ENCLOSED

Do not bend or fold AVOID EXPOSURE TO ALL MAGNETIC FIELDS

Inventors Names: Lin et al.

Invention Title:

GLIAL CELL LINE-DERIVED

NEUROTROPHIC FACTOR

Filing Date: Serial No.: May 23, 1994 08/182,183

Date Listing Prepared: January 3, 1996

Docket No.:

SYNE-225-E

MACINTOSH OPERATING SYSTEM 7.1/Microsoft Word 5.1a

Patentin Release 1.0 ver. l.25

04 Delph.

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND

Docker No.: SYNE-225E CARDUSSN: 08/182,183

Filed: 5/23/94

Inventors: Lin et al.

Title: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR

Including:

1 page Transmittal Letter w/ 1 copy

15 pages Response

1 computer readable disk containing sequence listing

12 pages sequence listing in written form

1 page Attorney Statement re: sequence listing

1 page Fee Transmittal and Extension of Time

DRC:n FIRST CLASS MAIL

January 5, 1996

by njw

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE
RECEIPT OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND
DOCKET NO.: SYNE-225E CARD USSN: 08/182,183 Filed: 5/23/94

Inventors: Lin et al.

Title: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR

Including:

____ page Transmittal Letter w/ 1 copy

15 pages Response

_1__ computer readable disk containing sequence listing

12 pages sequence listing in written form

1 page Attorney Statement re: sequence listing

1 page Fee Transmittal and Extension of Time

DRC:n FIRST CLASS MAIL

January 5, 1996

by njw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Lin, et al.

Group Art Unit:

1812

Serial No.:

08/182,183

Examiner:

Marianne P. Allen

Filed:

May 23, 1994

For:

GLIAL CELL LINE-DERIVED

NEUROTROPHIC FACTOR

Docket No.:

SYNE-225-E

(SYNE225/C4-US)

TRANSMITTAL OF RESPONSE TO OFFICE ACTION

Assistant Commissioner of Patents Washington, D. C. 20231

Sir:

Enclosed herewith are 1) the Response to the Office Action dated September 7, 1995 (i.e., Paper Number 20); 2) sequence listing in both computer readable format and in printed form and attorney statement pursuant to 37 C.F.R. 1.821(f); and 3) fee transmittal and petition for extension of time under 37 C.F.R. 1.136(a).

The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account 01-0519.

Respectfully submitted

Daniel R. Curry

Attorney for Applicants Registration No. 32,727 Phone: (805) 447-8102

Date: January 5, 1996

Please send all future correspondence to:
U.S. Patent Operations/DRC
M/S 10-1-B
AMGEN INC.
Amgen Center
1840 Dehavilland Drive
Thousand Oaks, California 91320-1789

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mall in an envelope addressed to Commissioner of

Patents and Trademarks, Washington, D.C. 20231, on the date appearing below

January 5, 1996

a J. Gryeth